search  
 


Home

Who are we?

Why
register?


Signup for
registration


Online registration

Log in to register
your trial


Search a trial

NRT en CCMO

Contact

NEDERLANDS





MetaRegister
van CCT (UK)


ISRCTN-Register
van CCT (UK)


24 resulaten gevonden voor HOVON in trials

A phase I/II feasibility study of the combination of panobinostat and midostaurin in recipients of allogeneic stem cell transplantation with Flt3-ITD AML
- TRIAL ID
NTR6511
- ACRONYMHOVON 148 AML
Efficacy and tolerability of ixazomib, daratumumab and low dose dexamethasone (IDd) followed by ixazomib and daratumumab maintenance therapy until progression for a maximum of 2 years in unfit and frail newly diagnosed multiple myeloma patients; an open-label phase II trial
- TRIAL ID
NTR6297
- ACRONYMHOVON 143 MM
A prospective, multicenter, phase-II trial of ibrutinib plus venetoclax in patients with creatinine clearance >= 30 ml/min who have relapsed or refractory chronic lymphocytic leukemia (RR-CLL) with or without TP53 aberrations
- TRIAL ID
NTR6249
- ACRONYMHOVON 141 CLL / VIsion Trial of the HOVON and Nordic CLL study groups
A prospective, open-label, multicenter randomized phase-II trial to evaluate the efficacy and safety of a sequential regimen of obinutuzumab (Gazyvaro) followed by obinutuzumab and venetoclax, followed by either standard venetoclax maintenance or MRD guided venetoclax maintenance in first-line patients with CLL and unfit for FCR-like regimens
- TRIAL ID
NTR6043
- ACRONYMHOVON 139 CLL
A randomized phase II multicenter study to assess the tolerability and efficacy of the addition of ibrutinib to 10-day decitabine in UNFIT (i.e. HCT-CI >= 3) AML and high risk myelodysplasia (MDS) (IPSS-R > 4.5) patients aged >= 66 years. A study in the frame of the masterprotocol of parallel randomized phase II studies in UNFIT-older AML/high-risk MDS patients.
- TRIAL ID
NTR6017
- ACRONYMHOVON 135 AML
A randomized phase II multicenter study with a safety run-in to assess the tolerability and efficacy of the addition of oral selinexor (KPT-330) to standard induction chemotherapy in AML and high risk myelodysplasia (MDS) (IPSS-R > 4.5) in patients aged >66 years .
- TRIAL ID
NTR5902
- ACRONYMHOVON 103 AML Selinexor
A phase II study evaluating the effect of the addition of lenalidomide to R-CHOP for patients with newly diagnosed MYC positive DLBCL and BCL-U.
- TRIAL ID
NTR5267
- ACRONYMHOVON 130 NHL
A prospective phase I/II trial of the combination of ixazomib citrate, rituximab and dexamethasone in patients wit relapsed or rogressive Waldenström’s macroglobiulinemia. A HOVON / Greek Myeloma Study Group study
- TRIAL ID
NTR5171
- ACRONYMHOVON 124 WM
Randomized study with a run-in dose-selection phase to assess the added value of lenalidomide in combination with standard remission-induction chemotherapy and post-remission treatment in patients aged 18-65 years with previously untreated acute myeloid leukemia (AML) or high risk myelodysplasia (MDS) (IPSS-R risk score > 4.5)
- TRIAL ID
NTR4376
- ACRONYMHOVON 132 AML
A phase I/II feasibility study of the combination of panobinostat and decitabine prior to donor lymphocyte infusion in recipients of allogeneic stem cell transplantation with poor and very poor-risk AML
- TRIAL ID
NTR4269
- ACRONYMHOVON 116 AML
Feasibility and Efficacy of dose adjusted Melphalan ¨C Prednisone ¨C Bortezomib (MPV) in elderly patients >= 75 years of age with newly diagnosed Multiple Myeloma; a non-randomised phase II study
- TRIAL ID
NTR4244
- ACRONYMHOVON 123 MM
Treatment of severe acute GVHD after allogeneic hematopoietic stem cell transplantation with steroids versus MSC and steroids. A prospective double-blind placebo-controlled randomized phase III trial
- TRIAL ID
NTR4228
- ACRONYMHOVON 112 MSC
Treatment of severe steroid-refractory acute GvHD with mesenchymal stromal cells. A phase III randomized double-blind multi-center HOVON study.
- TRIAL ID
NTR4227
- ACRONYMHOVON 113 MSC
Double umbilical cord blood transplantation in high-risk hematological patients.
A phase II study focussing on the mechanism of graft predominance.
- TRIAL ID
NTR3535
- ACRONYMHOVON 115 DOUBLE UCBT
A randomized phase II multicenter study with a safety run-in to assess the tolerability and efficacy of the addition of oral tosedostat to standard induction therapy in AML and RAEB ≥ 66 years and very poor risk AML ≥ 18 years.
- TRIAL ID
NTR2477
- ACRONYMHOVON 103 AML Tosedostat
Prognostic value of bone disease in MM, an evaluation of different imaging techniques at diagnosis and in follow-up.
- TRIAL ID
NTR2332
- ACRONYM
A randomized phase II multicenter study with a safety run-in to assess the tolerability and efficacy of the addition of oral lenalidomide to standard induction therapy in AML and RAEB ≥ 66 years and very poor risk AML ≥ 18 years.
- TRIAL ID
NTR2294
- ACRONYMHOVON 103 AML Lenalidomide
Randomized study with a run-in feasibility phase to assess the added value of Clofarabine in combination with standard remission-induction chemotherapy in patients aged 18-65 years with previously untreated acute myeloid leukemia (AML) or myelodysplasia (MDS) (RAEB with IPSS =>1.5).
- TRIAL ID
NTR2187
- ACRONYMHOVON 102 AML
Efficacy and safety of a single dose of 14.8 MBq/kg (0.4 mCi/kg)90Y-ibritumomab tiuxetan ("Zevalin") in elderly patients with diffuse large B-cell lymphoma and FDG-PET positive partial remission following first-line R-CHOP therapy. A Phase II clinical trial (HOVON 77).
- TRIAL ID
NTR2086
- ACRONYMHOVON 77 NHL
Clofarabine added to prephase and consolidation therapy in acute lymphoblastic leukemia in adults.
- TRIAL ID
NTR2004
- ACRONYMHOVON 100 ALL
Randomized maintenance therapy with Azacitidine (Vidaza) in older patients (>= 60 years of age) with acute myeloid leukemia (AML) and refractory anemia with excess of blasts (RAEB, RAEB-t).
- TRIAL ID
NTR1810
- ACRONYMHOVON 97 AML
Phase II study on the feasibility and efficacy of R-DHAP + HD-MTX, combined with intrathecal rituximab, followed by autologous stem cell transplantation in patients with a recurrent aggressive B-cell lymphoma with CNS localisation.
- TRIAL ID
NTR1757
- ACRONYMHOVON 80 NHL
Randomized phase III trial in elderly patients with previously untreated symptomatic Multiple Myeloma comparing MP-Thalidomide (MP-Thal) followed by thalidomide maintenance versus MP-Lenalidomide (MP-Len) followed by maintenance with lenalidomide.
- TRIAL ID
NTR1630
- ACRONYMHOVON 87 MM
A Phase II multicenter study to assess the tolerability and efficacy of the addition of Bevacizumab to standard induction therapy in AML and high risk MDS above 60 years.
- TRIAL ID
NTR904
- ACRONYMHOVON 81 AML